diagnost tool
price close busi june
diagnost tool
strong execut robust bull market go
street-high
robust return coverag univers sizzl ytd
vs see upsid ahead week sever top
compani deliv increment updat investor confer reinforc
long thesi note reiter buy rais pt
 rais pt street-high assign higher multipl
stock due rise likelihood launch test beyond
cologuard think liver cancer test opportun demonstr
sensit specif like launch initi ldt start
earli order off-label doc alreadi age
demograph time indic signific amount
data show efficaci posit cologuard age group
penetr within top health system tripl sale forc
target popul like continu add beyond fleet rep
hope captur follow news ac expand
recommend begin screen average-risk american begin age
estim age cohort rais compani cologuard tam
billion billion think may abl add anoth
american at-risk segment estim would take
cologuard dollar roughli billion
 rais pt street-high trade in-lin
revenue multipl group street ev/rev see ebitda multipl expans
street stock like abax trade
consensu estim respect recent indic mayb
give even focu sell triag bnp product aler
think continu molecular revenu hover rang previous
savanna exceed result solana busi
see good growth opportuni ou target doubl sofia
instal base doc offic hospit urgent care/retail
next year target placement across pharmaci us near term
catalyst ahead expect fda approv cw sofia lyme diseas test whole
blood summer longer term look menu expans across sofia solana
compel new molecular platform launch savanna eu us
 rais pt street-high assign higher
multipl stock follow announc increas us sale forc
take sale forc end come
littl surpris us sinc continu refin improv busi
think move part respons zts/abax merger howev indic
us contempl plan prior zts/abax deal think
lot learn sell diagnost think take time catch
expertis term headcount employ rep ou target
rep ww compar us ou said
hope on-board abaxi sale peopl upon deal close
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
pt use multipl adj ep estim
pt use multipl revenu estim
million discount back year discount rate use million share
pt use multipl revenu estim
million discount back year discount rate use million share
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin june et
date time product june et
pt use multipl revenu estim million discount back year discount
pt use multipl adj ep estim y/i
pt use multipl revenu estim million discount back year discount rate
risk achiev target price valuat
risk model includ number new physician add per quarter physician re-ord rate level
 spend cologuard re-ord year first cologuard user due re-screen
pama pama establish medicar price base weight median commerci payor rate pama present
expect go effect januari though time could push opinion view risk
small none given view pama rate like remain similar present medicar rate
competit mani compani develop colorect screen modal particularli blood test liquid biopsi
compani includ grail name three test like fobt fecal occult blood test
fecal immunochem test use year mani new test offer cancer detect uncertain competit
develop test proven pre-canc claim
reimburs pursu health plan coverag privat commerci payor assur health plan
elect cover cologuard uncertainti price might reimburs test
note typic medic technolog risk risk includ commerci execut sale market team regulatori risk
fda potenti product recal patent infring product liabil lawsuit anti-trust litig
commerci execut season ebb flow involv direct sell primari care physician gi
assur abl meet exceed guidanc provid quarter-to-quart
valuat trade continu trade meaning premium us healthcar compani compani
 result guarante continu trade higher even abl exceed guidanc
util anim health underli demand anim health patient offic visit strong steadi year idexx
could see pressur event underli anim health util reach peak level turn could impli difficult
econom pressur unemploy rate tick lower rel level seen great recess variou
macroeconom headwind could reduc demand diagnost pet servic econom weak could caus pet owner skip
diagnost tool
defer visit vet hospit could affect owner willing approv certain diagnost test compli treatment plan
even continu own pet
larg intern exposur deriv revenu outsid north america intern growth rate
commonli exceed unit state guarante occur futur believ intern growth
volatil growth rate us addit currenc fluctuat intern sale may continu
advers impact revenu earn
competit competit veterinari diagnost market high time intens although vet diagnost market
less duopoli compani compet commerci clinic lab hospit clinic lab manufactur multi-test blood
analyz on-sit test system expect competit abaxi particular remain rel high
regulatori risk product subject usda foreign regulatori agenc respect product
approv manufactur market promot label record keep test qualiti storag product dispos howev
regulatori risk lower human medic compani
invest risk includ larg varianc season respiratori product relat incid respiratori ill like
influenza accuraci annual influenza vaccin competit particularli establish molecular diagnost
compani product develop delay fda regulatori risk includ pma clia-waiv submiss emerg
altern over-the-count over-the-counter market new rapid molecular technolog cannib rapid test offer commerci risk
common medic technolog risk
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
exact scienc current past month client canaccord genuiti affili compani period
canaccord genuiti affili compani provid invest bank servic
past month canaccord genuiti affili compani receiv compens invest bank servic
past month canaccord genuiti affili compani lead manag co-lead manag co-manag
public offer secur publicli disclos offer secur relat deriv
diagnost tool
canaccord genuiti one affili compani market maker liquid provid secur
laboratori relat deriv
canaccord genuiti one affili compani intend seek expect receiv compens invest bank
servic next three month
analyst visit materi oper payment receiv relat travel cost
rate histori
rate histori
rate histori
diagnost tool
line articl mifid ii deleg regul disclos price perform preced five year whole period
financi instrument offer invest servic provid less five year pleas note price histori
refer actual past perform past perform reliabl indic futur price and/or perform
